These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24504151)

  • 1. Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa.
    Manasa J; Lessells R; Rossouw T; Naidu K; Van Vuuren C; Goedhals D; van Zyl G; Bester A; Skingsley A; Stott K; Danaviah S; Chetty T; Singh L; Moodley P; Iwuji C; McGrath N; Seebregts CJ; de Oliveira T
    Database (Oxford); 2014; 2014():bat082. PubMed ID: 24504151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
    Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
    PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 subtypes B and C unique recombinant forms (URFs) and transmitted drug resistance identified in the Western Cape Province, South Africa.
    Jacobs GB; Wilkinson E; Isaacs S; Spies G; de Oliveira T; Seedat S; Engelbrecht S
    PLoS One; 2014; 9(6):e90845. PubMed ID: 24609015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Status of resistance of HIV-1 strains in Africa: what is the role of viral surveillance networks?].
    Grandadam M; Nicand E; Koeck JL; Caron M; Teyssou R
    Med Trop (Mars); 2002; 62(1):89-93. PubMed ID: 12038188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study.
    Drescher SM; von Wyl V; Yang WL; Böni J; Yerly S; Shah C; Aubert V; Klimkait T; Taffé P; Furrer H; Battegay M; Ambrosioni J; Cavassini M; Bernasconi E; Vernazza PL; Ledergerber B; Günthard HF; Kouyos RD;
    Clin Infect Dis; 2014 Jan; 58(2):285-94. PubMed ID: 24145874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
    Marconi VC; Sunpath H; Lu Z; Gordon M; Koranteng-Apeagyei K; Hampton J; Carpenter S; Giddy J; Ross D; Holst H; Losina E; Walker BD; Kuritzkes DR;
    Clin Infect Dis; 2008 May; 46(10):1589-97. PubMed ID: 18419495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
    Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF;
    Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and uses of a public HIV drug-resistance database.
    Shafer RW
    J Infect Dis; 2006 Sep; 194 Suppl 1(Suppl 1):S51-8. PubMed ID: 16921473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.
    Avidor B; Turner D; Mor Z; Chalom S; Riesenberg K; Shahar E; Pollack S; Elbirt D; Sthoeger Z; Maayan S; Olshtain-Pops K; Averbuch D; Chowers M; Istomin V; Anis E; Mendelson E; Ram D; Levy I; Grossman Z
    PLoS One; 2013; 8(3):e57789. PubMed ID: 23469241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.
    Lessells RJ; Avalos A; de Oliveira T
    AIDS Rev; 2013; 15(4):221-9. PubMed ID: 24322382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary drug resistance in South Africa: data from 10 years of surveys.
    Manasa J; Katzenstein D; Cassol S; Newell ML; de Oliveira T;
    AIDS Res Hum Retroviruses; 2012 Jun; 28(6):558-65. PubMed ID: 22251009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
    Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
    PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
    Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
    PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-infected Pediatric Population in Madrid: 1993 to 2015 Analysis.
    Rojas Sánchez P; Domínguez S; Jiménez De Ory S; Prieto L; Rojo P; Mellado P; Navarro M; Delgado R; Ramos JT; Holguín Á;
    Pediatr Infect Dis J; 2018 Mar; 37(3):e48-e57. PubMed ID: 28991889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
    Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa.
    Hauser A; Kusejko K; Johnson LF; Wandeler G; Riou J; Goldstein F; Egger M; Kouyos RD
    PLoS Comput Biol; 2019 Jun; 15(6):e1007083. PubMed ID: 31233494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom.
    Chilton DN; Castro H; Lattimore S; Harrison LJ; Fearnhill E; Delpech V; Rice B; Pillay D; Dunn DT;
    Antivir Ther; 2010; 15(7):985-91. PubMed ID: 21041913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on HIV-1 acquired and transmitted drug resistance in Africa.
    Ssemwanga D; Lihana RW; Ugoji C; Abimiku A; Nkengasong J; Dakum P; Ndembi N
    AIDS Rev; 2015; 17(1):3-20. PubMed ID: 25427100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
    Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W;
    Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.